Bard Acquires Vacuum-Assisted Biopsy Device.Business Editors/Health/Medical Writers MURRAY HILL, N.J.--(BUSINESS WIRE)--July 24, 2003 C. R. Bard C. R. Bard, Inc. (NYSE: BCR) is one of the large S&P 500 companies of the United States, a surgical specialties and hospital medical device manufacturer in Murray Hill, New Jersey. It is named after its founder, who sold the company within only a few years of its founding. , Inc. (NYSE NYSE See: New York Stock Exchange :BCR BCR B Cell Receptor BCR Business Communications Review (magazine) BCR Banca Comerciala Romana (Romanian bank) BCR Breakpoint Cluster Region BCR Benefit/Cost Ratio BCR Bay City Rollers ) today announced that it has acquired assets related to the manufacture and distribution of a new biopsy device from BIP BIP - An incorrect singular of BIPS. One billion instructions per second is 1 BIPS, not 1 BIP. Biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. Instruments and Products GmbH (BIP), located in Turkenfeld, Germany. Bard Peripheral Vascular, Inc., Bard's subsidiary located in Tempe, Arizona, will market the product. Terms of the transaction were not disclosed. The new minimally invasive device has a proprietary vacuum-assisted design. It is initially targeted at breast biopsies, for which there are an estimated 2.3 million procedures performed annually around the world. Approximately half of these procedures are performed using less invasive biopsy devices with the balance done surgically. Bard's new biopsy product is a self-contained, portable unit that fits into the physician's hand, providing optimal control, accuracy and flexibility for biopsy procedures. The device is suitable for use with a range of imaging technologies including stereotactic stereotactic /ster·eo·tac·tic/ (-tak´tik) 1. characterized by precise positioning in space; said especially of discrete areas of the brain that control specific functions. 2. pertaining to stereotactic surgery. x-ray and ultrasound. In 1995, Bard acquired BIP's Magnum(R) core needle biopsy needle biopsy n. Removal of a specimen for biopsy by aspirating it through a needle or trocar that pierces the skin or the external surface of an organ and continues into the underlying tissue to be examined. Also called aspiration biopsy. device, which is the current market leader for spring-loaded core needle biopsies. William H. Longfield, chairman and chief executive officer, commented, "This acquisition leverages our market leadership position in core needle biopsy, enabling us to enter the larger and faster growing vacuum-assisted segment. It is consistent with our objective to acquire early stage technology to enhance our franchises and improve our sales growth." The company said that this transaction does not change its guidance for 2003. This press release contains forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. Please refer to our March 31, 2003, Form 10-Q for a statement with regard to forward-looking statements, including disclosure of additional factors that could cause actual results to differ materially from those expressed or implied. C. R. Bard, Inc., (www.crbard.com) headquartered in Murray Hill, N.J., is a leading multinational developer, manufacturer, and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion